Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia | Zendy

Joshua Wolf | Zendy; Li Tang | Zendy; Patricia M. Flynn | Zendy; ChingHon Pui | Zendy; Aditya H. Gaur | Zendy; Yilun Sun | Zendy; Hiroto Inaba | Zendy; Tracy B. Stewart | Zendy; Randall T. Hayden | Zendy; Hana Hakim | Zendy; Sima Jeha | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia

Author(s) -

Joshua Wolf,

Li Tang,

Patricia M. Flynn,

ChingHon Pui,

Aditya H. Gaur,

Yilun Sun,

Hiroto Inaba,

Tracy B. Stewart,

Randall T. Hayden,

Hana Hakim,

Sima Jeha

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix644

Subject(s) - medicine , levofloxacin , lymphoblastic leukemia , acute lymphocytic leukemia , induction therapy , leukemia , intensive care medicine , chemotherapy , immunology , antibiotics , microbiology and biotechnology , biology

Infection is the most important cause of treatment-related morbidity and mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although routine in adults with leukemia, antibacterial prophylaxis is controversial in pediatrics because of insufficient evidence for its efficacy or antibiotic choice and concerns about promoting antibiotic resistance and Clostridium difficile infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research